Wall Street analysts forecast that Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) will announce sales of $50,000.00 for the current quarter, according to Zacks. Three analysts have made estimates for Aurinia Pharmaceuticals’ earnings, with the highest sales estimate coming in at $100,000.00 and the lowest estimate coming in at $30,000.00. Aurinia Pharmaceuticals reported sales of $380,000.00 during the same quarter last year, which would suggest a negative year over year growth rate of 86.8%. The company is scheduled to announce its next earnings results on Thursday, November 14th.

According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full-year sales of $150,000.00 for the current financial year, with estimates ranging from $120,000.00 to $200,000.00. For the next year, analysts expect that the firm will report sales of $150,000.00, with estimates ranging from $120,000.00 to $200,000.00. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that that provide coverage for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.08% and a negative net margin of 13,231.97%.

Several brokerages recently issued reports on AUPH. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Aurinia Pharmaceuticals in a report on Tuesday, June 4th. Zacks Investment Research lowered Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. Royal Bank of Canada reiterated a “buy” rating and set a $11.00 price objective on shares of Aurinia Pharmaceuticals in a report on Thursday, August 8th. Finally, BidaskClub upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 15th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $15.65.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Orbimed Advisors LLC raised its position in Aurinia Pharmaceuticals by 12.1% in the second quarter. Orbimed Advisors LLC now owns 3,531,002 shares of the biotechnology company’s stock worth $23,234,000 after acquiring an additional 381,192 shares during the period. UBS Asset Management Americas Inc. bought a new stake in shares of Aurinia Pharmaceuticals in the second quarter valued at approximately $88,000. Point72 Asset Management L.P. raised its position in shares of Aurinia Pharmaceuticals by 670.2% in the second quarter. Point72 Asset Management L.P. now owns 22,083 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 19,216 shares during the period. Vanguard Group Inc. raised its position in shares of Aurinia Pharmaceuticals by 18.6% in the second quarter. Vanguard Group Inc. now owns 29,020 shares of the biotechnology company’s stock valued at $191,000 after purchasing an additional 4,549 shares during the period. Finally, A.R.T. Advisors LLC raised its position in shares of Aurinia Pharmaceuticals by 44.9% in the second quarter. A.R.T. Advisors LLC now owns 18,395 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 5,700 shares during the period. Institutional investors own 31.82% of the company’s stock.

Shares of NASDAQ:AUPH traded down $0.04 during midday trading on Thursday, hitting $5.86. 292,182 shares of the stock were exchanged, compared to its average volume of 691,251. Aurinia Pharmaceuticals has a 52-week low of $5.06 and a 52-week high of $7.85. The business’s fifty day simple moving average is $6.15 and its two-hundred day simple moving average is $6.36. The company has a market capitalization of $530.43 million, a PE ratio of -7.71 and a beta of 1.09.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Further Reading: Average Daily Trade Volume – What You Need to Know

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.